Single-Dose Safety Study of APD791 in Healthy Volunteers

Arena Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: APD791

Study type: Interventional

Funder types: Industry

Identifiers

NCT00529646

APD791-001

Details and patient eligibility

About

The APD791-001 study is designed primarily to evaluate the safety and tolerability of APD791 when administered as a single oral dose to healthy adult subjects.

Enrollment: 90 estimated patients

Sex: All

Ages: 19 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adult men and women, ages 19-45
• Non smokers

Exclusion criteria

• History of a bleeding disorder
• Recently donated blood or had significant blood loss
• Current use of a prescription medication
• Pregnant females